Oncolytics Biotech’s CMO departs on cusp of phase 3 trial

Red Exit sign
(Leeroy Agency)

Oncolytics Biotech has lost its CMO shortly before it is due to start a pivotal metastatic breast cancer trial. Andres Gutierrez, M.D., Ph.D., is leaving to pursue other opportunities after spending 18 months as CMO of the Canadian microcap.

Gutierrez arrived at Oncolytics shortly after it parted company with its CEO, Brad Thomson. Together with Thomson’s replacement, Matt Coffey, Ph.D., Gutierrez formed part of a new-look executive team tasked with guiding the immuno-oncolytic virus specialist back from setbacks that caused its stock to fall by more than 90% in the years preceding their appointments.

That effort remains unfinished. But Coffey framed the timing of Gutierrez’s departure as falling at a natural cutoff point, stating that he arrived with “a mandate to position and prepare the company for a phase 3 study.” That part of Oncolytics’ attempt to bounce back is done.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Having played a pivotal role in developing a comprehensive clinical development plan and the design of our phase 3 study in HR-positive, HER2-negative metastatic breast cancer required for approval, his work culminated in the submission to receive a special protocol assessment from the FDA,” Coffey said in a statement.

The task of running the phase 3 still awaits Oncolytics, though. Gutierrez is leaving effective April 23, and Oncolytics is now searching for a replacement to work out of its San Diego office. In the interim, the clinical and regulatory teams Gutierrez leaves behind will guide Oncolytics toward first patient in.

Oncolytics is looking to the trial for evidence its type 3 reovirus pelareorep improves outcomes in patients with HR-positive, HER2-negative metastatic breast cancer. The candidate is designed to take out tumors by causing the disintegration of cells, which, in turn, triggers innate and adaptive immune responses.

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.